Jouni Vuorinen

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F2α analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently(More)
  • 1